Practice alert: FDA approves Zinecard.
Barhamand
B
B
D001943:Breast Neoplasms / Q000188:drug therapy*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000188:drug therapy; D002614:Chelating Agents / Q000627:therapeutic use*; D003630:Daunorubicin / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D002614:Chelating Agents; D004317:Doxorubicin; D003630:Daunorubicin